Abstract: Niraparib (MK-4827) is a highly selective, orally bioavailable poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitor. While it has achieved global approval for the maintenance therapy of ovarian cancer, its therapeutic potential in breast cancer—particularly in human epidermal growth factor receptor 2 (HER2)-negative, BRCA-mutated, and triple-negative breast cancer (TNBC)—has been a major focus of recent oncological research. This review synthesizes the pharmacological activity, molecular mechanisms, and structure-activity relationships of niraparib. It highlights key clinical trials in breast cancer, such as the BRAVO and TOPACIO studies, which demonstrate its efficacy as a monotherapy and in combination with immune checkpoint inhibitors. Furthermore, this review addresses current limitations, including hematological toxicities, cardiovascular side effects, and resistance mechanisms, and outlines future perspectives for integrating niraparib into earlier treatment settings and novel combination regimens for breast cancer.
1. Introduction
Breast cancer remains the most frequent cancer and a leading cause of cancer-related mortality in women worldwide [9]. A significant subset of breast cancers, particularly triple-negative breast cancer (TNBC), harbors germline or somatic mutations in the BRCA1 and BRCA2 genes, which are critical for the homologous recombination (HR) DNA repair pathway [2]. The discovery that BRCA-deficient cells are profoundly sensitive to PARP inhibition through the concept of synthetic lethality has revolutionized targeted cancer therapy [8]. Niraparib (MK-4827) is a potent, once-daily, oral PARP1/2 inhibitor that has demonstrated substantial clinical benefit and received global approval for the maintenance treatment of gynecological malignancies [1]. Building on its success in ovarian cancer, extensive preclinical and clinical research has been directed toward evaluating niraparib in breast cancer, aiming to exploit homologous recombination deficiency (HRD) to induce tumor cell death and improve patient outcomes [2].
2. Pharmacological Activity
Niraparib exhibits robust anti-tumor efficacy in BRCA-mutated and HRD-positive breast cancer models. Preclinical studies have shown that niraparib can cross the blood-brain barrier in rodents, achieving brain-to-plasma concentration ratios of 0.85 to 0.99. It has demonstrated therapeutic efficacy in BRCA2-mutant intracranial tumor models, a finding that is highly relevant for breast cancer patients who frequently develop brain metastases [1][5].
In the clinical setting, niraparib has been evaluated across multiple breast cancer trials. The phase III BRAVO trial (NCT01905592) compared niraparib to physician's choice chemotherapy in patients with HER2-negative, germline BRCA-mutated advanced or metastatic breast cancer. Although the study was prematurely closed due to a high dropout rate in the control arm, niraparib demonstrated a median progression-free survival (PFS) of 4.1 to 5.0 months compared to 3.1 months for the control [2][4]. In the phase II TOPACIO trial (NCT02657889), the combination of niraparib and the PD-1 inhibitor pembrolizumab in advanced TNBC yielded an objective response rate (ORR) of 21% in the overall population and 47% in patients with tumor BRCA mutations, alongside a disease control rate (DCR) of 80% in the mutated subgroup [2]. Furthermore, pilot studies (e.g., NCT03329937) evaluating niraparib as a neoadjuvant treatment for localized HER2-negative, BRCA-mutated breast cancer reported a high tumor response rate of 89% as measured by MRI [2].
Pharmacokinetically, niraparib has an absolute oral bioavailability of approximately 73% and a long terminal half-life of 36 to 59 hours, supporting a convenient once-daily dosing regimen [1][10]. It is primarily metabolized in the liver via carboxylesterase-catalyzed amide hydrolysis into an inactive metabolite (M1), with negligible involvement of cytochrome P450 enzymes [1].
3. Molecular Mechanism of Action
Niraparib exerts its anti-tumor effects primarily by inhibiting PARP-1 and PARP-2, enzymes essential for the base excision repair (BER) of single-strand DNA breaks [6]. By competing with NAD+ at the catalytic domain, niraparib blocks PARP enzymatic activity [8]. In tumors with BRCA1/2 mutations or other HR deficiencies, the unrepaired single-strand breaks degenerate into highly toxic double-strand breaks during DNA replication. Because the error-free HR pathway is impaired, the cell is forced to rely on error-prone repair mechanisms like non-homologous end joining (NHEJ), leading to genomic instability, chromosomal collapse, and apoptotic cell death—a phenomenon known as synthetic lethality [2][8].
Additionally, niraparib acts as a potent "PARP trapper." It traps PARP-DNA complexes at the site of DNA damage, which is significantly more cytotoxic than catalytic inhibition alone. Niraparib's trapping potency is higher than that of olaparib and rucaparib, though slightly less than that of talazoparib [2]. Beyond DNA repair, niraparib has been found to inhibit neuronal dopamine, norepinephrine, and serotonin transporters, which accounts for some of its off-target cardiovascular effects [5][10].
4. Structure-Activity Relationship (SAR)
Niraparib (MK-4827) is chemically designated as 2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide [1]. Its molecular structure was specifically optimized to overcome the weak potency associated with early PARP inhibitors, which was caused by the free rotation of the amide bond. While other PARP inhibitors like olaparib and rucaparib utilize an amide ring to restrain this rotation, niraparib employs a distinct structural strategy. It positions a hydrogen bond-accepting group such that the NH anti-carbonyl amide forms an intracellular hydrogen bond [3]. This conformational restriction allows niraparib to bind tightly to the catalytic domain of PARP enzymes, resulting in highly selective and potent inhibition of PARP-1 (IC50 = 3.8 nM) and PARP-2 (IC50 = 2.1 nM) [3][6].
5. Current Limitations
Despite its efficacy, the clinical application of niraparib in breast cancer faces several limitations. The most significant dose-limiting toxicities are hematological, including thrombocytopenia, anemia, and neutropenia, which often require dose modifications or interruptions [1][7]. Non-hematological adverse events include fatigue, nausea, and insomnia. Uniquely among PARP inhibitors, niraparib's off-target inhibition of monoamine transporters can lead to cardiovascular side effects, such as hypertension, hypertensive crisis, and tachycardia, necessitating regular blood pressure and pulse monitoring [7][10].
Acquired resistance remains a major hurdle. Mechanisms of resistance include secondary reversion mutations in BRCA1/2 that restore HR proficiency, downregulation of PARP enzymes, and the upregulation of drug efflux pumps, as niraparib is a known substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) [5][8]. Furthermore, clinical trial execution has presented challenges; the premature closure of the phase III BRAVO trial due to a high rate of discontinuation in the control arm hindered the establishment of niraparib as a standard monotherapy registration for breast cancer, leaving it trailing behind olaparib and talazoparib in this specific indication [2].
6. Future Perspectives
The future of niraparib in breast cancer lies in expanding its utility beyond monotherapy in advanced disease. Combining niraparib with immune checkpoint inhibitors (e.g., pembrolizumab) has shown synergistic potential in TNBC by leveraging the DNA damage-induced immune response, and further phase III trials are warranted to confirm these benefits [2]. Combinations with other targeted agents, such as anti-angiogenics or inhibitors of ATR, CHK1, and WEE1, are also being explored to overcome intrinsic and acquired resistance [7].
There is a strong rationale for moving niraparib into the neoadjuvant and adjuvant settings for high-risk, localized BRCA-mutated breast cancer, where it may eradicate micrometastases and improve long-term survival [2][9]. Finally, refining companion diagnostics (such as the myChoice HRD test) to accurately identify non-BRCA mutated breast cancer patients who exhibit "BRCAness" will be crucial for expanding the patient population that can benefit from niraparib therapy [1].
